A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients

Acta Psychiatrica Scandinavica
J De WildeS Leyman

Abstract

A randomized, double-blind, parallel-group, 6-week study was undertaken to compare the efficacy and tolerability of once or twice daily administration of the selective serotonin reuptake inhibitors paroxetine and fluoxetine. After a 1-week placebo wash-out, patients suffering from DSM-III major depression and with a score of 18 or more on the 21-item Hamilton Rating Scale for Depression (HRSD) received either paroxetine or fluoxetine. The patients were assessed for efficacy using the HRSD, Montgomery-Asberg Depression Rating Scale and Clinical Global Impression; for tolerability, adverse events were elicited by the use of a non-leading question and a side effects checklist. The groups of patients were comparable on entry to the study. One hundred patients were recruited into the study, of whom 78 were evaluable for the efficacy analysis. Paroxetine and fluoxetine showed comparable efficacy at the end of the 6-week treatment period, but a statistically significant difference in the number of responders at week 3 in favour of paroxetine was observed. This could suggest an earlier onset of action with paroxetine. Also, associated anxiety symptoms were significantly reduced on paroxetine compared with fluoxetine at week 3. Patients...Continue Reading

References

Jun 1, 1992·International Clinical Psychopharmacology·G C Dunbar, D L Fuell
Sep 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·G C DunbarR K Shrivastava
Jan 1, 1989·Acta Psychiatrica Scandinavica. Supplementum·J P Feighner, W F Boyer
Sep 1, 1974·Archives of General Psychiatry·J L ClaghornL Itschner

❮ Previous
Next ❯

Citations

Oct 31, 2002·Human Psychopharmacology·Johan A. Den BoerBernhard R. Slaap
Jul 14, 1999·Journal of Affective Disorders·G ChouinardM C O'Neill
Apr 15, 2009·Journal of Child and Adolescent Psychopharmacology·Charles A HenryMargaret Bauman
Feb 24, 1998·Journal of Clinical Psychopharmacology·R D MarshallM R Liebowitz
Jun 23, 2004·Journal of Clinical Psychopharmacology·Corrado BarbuiMatthew Hotopf
Oct 6, 2000·Acta Psychiatrica Scandinavica. Supplementum·S PerettiI Hindmarch
Mar 27, 2009·Psychotherapy and Psychosomatics·Bret R RutherfordSteven P Roose
Mar 22, 2006·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Ivy Q Tonnu MiharaBradley R Williams
Jan 7, 1998·Clinical Therapeutics·P E Stokes, A Holtz
Oct 24, 2013·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Ying WangQianping Wei
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S Mace, D Taylor
Jun 1, 2008·Current Therapeutic Research, Clinical and Experimental·Changsu HanIn-Kwa Jung
Jul 26, 2000·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·E Weber Reynolds CF3rd
Aug 29, 2000·Inflammatory Bowel Diseases·L B Gerson, G Triadafilopoulos
Apr 1, 1997·Clinical Pharmacology and Therapeutics·J G ModellR L DePalma
Apr 4, 2014·The Cochrane Database of Systematic Reviews·Marianna PurgatoCorrado Barbui
Feb 1, 1996·Journal of Clinical Psychopharmacology·R D Marshall, M R Liebowitz
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
Oct 1, 1995·Human Psychopharmacology·S J Van den Berg
Sep 2, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gerald GartlehnerKathleen N Lohr
Jan 1, 1995·Journal of Psychopharmacology·R LaneS Preskorn
Oct 1, 1993·The Annals of Pharmacotherapy·C F Caley, S S Weber
May 1, 1996·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·U Schnyder, A Koller-Leiser
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
Mar 10, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Scott PattenCorrado Barbui
Dec 20, 2013·The Cochrane Database of Systematic Reviews·Laura R MagniCorrado Barbui
Oct 1, 1995·Human Psychopharmacology·S Kasper, A Heiden
Mar 6, 2004·Bipolar Disorders·Benjamin J D H Chun, David L Dunner

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.